Pancreatic Cancer Research

ResearcherNorth Dakota State UniversityActive in the last 2 years

Sanku Mallik

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-4236-2512; OpenAlex author ID A5044523133; NIH RePORTER profile ID 7938205. Sources: OpenAlex.

Their work

Papers
16 (first author 1, last author 7)
Trials
0
Grants
1
Labs led
1
Collaborators
43
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 1 paper · 2015: none · 2016: 4 papers · 2017: 1 paper · 2018: 1 paper · 2019: 3 papers · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 1 paper, 1 grant

Papers 16

  1. Nanoparticles for Delivery of Encapsulated Drugs to Hypoxic Pancreatic Ductal Adenocarcinoma Cell Spheroids. Last author DOI 10.1021/acs.molpharmaceut.5c01395↗
  2. Nanocarrier mediated entinostat and oxaliplatin combination therapy displayed enhanced efficacy against pancreatic cancer. Co-author DOI 10.1016/j.biopha.2024.116743↗
  3. An intravenous pancreatic cancer therapeutic: Characterization of CRISPR/Cas9n-modified Clostridium novyi-Non Toxic. Co-author DOI 10.1371/journal.pone.0289183↗
  4. Single-Molecule Force Probing of RGD-Binding Integrins on Pancreatic Cancer Cells. Co-author DOI 10.1021/acsami.1c23361↗
  5. pH-Sensitive Nanodrug Carriers for Codelivery of ERK Inhibitor and Gemcitabine Enhance the Inhibition of Tumor Growth in Pancreatic Cancer. Co-author DOI 10.1021/acs.molpharmaceut.0c00499↗
  6. Microenvironment-sensing, nanocarrier-mediated delivery of combination chemotherapy for pancreatic cancer. Co-author DOI 10.1007/s12079-019-00514-w↗
  7. PEG-b-poly (carbonate)-derived nanocarrier platform with pH-responsive properties for pancreatic cancer combination therapy. Co-author DOI 10.1016/j.colsurfb.2018.10.069↗
  8. CYR61/CCN1 Regulates dCK and CTGF and Causes Gemcitabine-resistant Phenotype in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1535-7163.mct-18-0899↗
  9. Nucleus-Targeted, Echogenic Polymersomes for Delivering a Cancer Stemness Inhibitor to Pancreatic Cancer Cells. Last author DOI 10.1021/acs.biomac.8b01133↗
  10. Nuclear Localizing Peptide-Conjugated, Redox-Sensitive Polymersomes for Delivering Curcumin and Doxorubicin to Pancreatic Cancer Microtumors. Last author DOI 10.1021/acs.molpharmaceut.7b00014↗
  11. Acridine Orange Conjugated Polymersomes for Simultaneous Nuclear Delivery of Gemcitabine and Doxorubicin to Pancreatic Cancer Cells. Last author DOI 10.1021/acs.bioconjchem.5b00694↗
  12. Hypoxia Responsive, Tumor Penetrating Lipid Nanoparticles for Delivery of Chemotherapeutics to Pancreatic Cancer Cell Spheroids. Last author DOI 10.1021/acs.bioconjchem.6b00241↗
  13. Hypoxia-Responsive Polymersomes for Drug Delivery to Hypoxic Pancreatic Cancer Cells. Last author DOI 10.1021/acs.biomac.6b00350↗
  14. Biomarkers and Targeted Therapy in Pancreatic Cancer. First author DOI 10.4137/bic.s34414↗
  15. Mmp-9 responsive PEG cleavable nanovesicles for efficient delivery of chemotherapeutics to pancreatic cancer. Last author DOI 10.1021/mp500108p↗
  16. Advances in biomarker research for pancreatic cancer. Co-author DOI 10.2174/13816128112092439↗

Grants 1

  1. Biostatistics and Bioinformatics Core Facility P20GM109024↗

Closest collaborators

The 25 strongest of 43 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yongki Choi · 7 shared papers, 1 shared grant, 2016–2026 · strength 1.24
  2. Katie M. Reindl · 4 shared papers, 1 shared grant, 2014–2026 · strength 0.95
  3. Mohiuddin Quadir · 3 shared papers, 1 shared grant, 2019–2026 · strength 0.78
  4. Megan Orr · 2 shared papers, 1 shared grant, 2021–2026 · strength 0.75
  5. Buddhadev Layek · 1 shared paper, 1 shared grant, 2024–2026 · strength 0.70
  6. Jiha Kim · 1 shared paper, 1 shared grant, 2022–2026 · strength 0.62
  7. Bin Guo · 1 shared paper, 1 shared grant, 2014–2026 · strength 0.50
  8. Erxi Wu · 1 shared paper, 1 shared grant, 2012–2026 · strength 0.50
  9. Sathish Venkatachalem · 1 shared grant, 2026 · strength 0.46
  10. Ang Guo · 1 shared grant, 2026 · strength 0.46
  11. Mark T Hamann · 1 shared grant, 2026 · strength 0.46
  12. Roberto Gomes · 1 shared grant, 2026 · strength 0.46
  13. Jagdish Singh · 1 shared grant, 2026 · strength 0.46
  14. Estelle Leclerc · 1 shared grant, 2026 · strength 0.46
  15. John Curlee Wilkinson · 1 shared grant, 2026 · strength 0.46
  16. Elisabetta Liverani · 1 shared grant, 2026 · strength 0.46
  17. Guodong Liu · 1 shared grant, 2026 · strength 0.46
  18. Rick J. Jansen · 1 shared grant, 2026 · strength 0.46
  19. Priyanka Ray · 3 shared papers, 2019–2021 · strength 0.32
  20. Sushanta K. Banerjee · 3 shared papers, 2019–2021 · strength 0.29
  21. Snigdha Banerjee · 3 shared papers, 2019–2021 · strength 0.29
  22. Chukwuebuka Ozoude · 1 shared paper, 2026 · strength 0.28
  23. Philip Salu · 1 shared paper, 2024 · strength 0.24
  24. Paras Mani Giri · 1 shared paper, 2024 · strength 0.24
  25. Gauthami Nair · 2 shared papers, 2019–2021 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.